Monitoring of the body’s blood sugar is essential to the treatment of diabetes. But getting effective glucose readings has ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Trinity Biotech plc has announced encouraging results from its recent pre-pivotal clinical trial of its next-generation continuous glucose monitoring (CGM) system, targeting diabetes management.

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes. Glucotrack’s CBGM is a long-term, implantable system that ...

This study represents the first real-time, continuous blood glucose monitor (CBGM ... While neither the study nor prototype system was designed to evaluate sensor accuracy, the system performed ...

The company also appointed Ted Williams as Vice President of Regulatory Affairs to advance their continuous blood glucose monitoring system. Glucotrack issued 134.78 million shares of common stock ...

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling ...

Trinity stock is trading higher on Tuesday after the company announced results from its pre-pivotal clinical trial for its ...

implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it has filed for CE Mark registration for the Eversense ® 365 CGM system. Eversense 365 is the ...